Browse by category

There is no link between semaglutide (a glucagon-like peptide-1 receptor agonist, GLP-1RA) use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway, according to at the Annual Meeting of The European Association for the Study of Diabetes (EASD). This regulator-mandated post authorisation study, funded by Novo Nordisk, was presented by Professor Anton Pottegård, University of Southern Denmark, Odense, Denmark, and colleagues. “This comprehensive